Approaches to handling pharmacodynamic baseline responses
暂无分享,去创建一个
[1] R. Ramakrishnan,et al. Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers , 2004, Journal of clinical pharmacology.
[2] J. Vonderscher,et al. Population pharmacodynamic analysis of octreotide in acromegalic patients , 2003, Clinical pharmacology and therapeutics.
[3] Ronald Gieschke,et al. An Integrated Model for Glucose and Insulin Regulation in Healthy Volunteers and Type 2 Diabetic Patients Following Intravenous Glucose Provocations , 2007, Journal of clinical pharmacology.
[4] E. Niclas Jonsson,et al. PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..
[5] F. Schindel. Consideration of endogenous backgrounds in pharmacokinetic analyses: a simulation study , 2000, European Journal of Clinical Pharmacology.
[6] Yasue Kobayashi,et al. A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection. , 2004, British journal of clinical pharmacology.
[7] E. Niclas Jonsson,et al. Erratum to "PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM" [Comput. Methods Prog. Biomedicine 79 (2005) 241-257] , 2005, Comput. Methods Programs Biomed..
[8] W. Jusko,et al. Role of baseline parameters in determining indirect pharmacodynamic responses. , 1999, Journal of pharmaceutical sciences.
[9] J. Mordenti,et al. Design of Biological Equivalence Programs for Therapeutic Biotechnology Products in Clinical Development: A Perspective , 1996, Pharmaceutical Research.
[10] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[11] S. Higuchi,et al. Pharmacokinetic and pharmacodynamic analysis of TS‐943, a selective non‐peptide platelet glycoprotein‐IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs , 2002, The Journal of pharmacy and pharmacology.
[12] Mats O Karlsson,et al. Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. , 2004, British journal of clinical pharmacology.
[13] A. Munafo,et al. The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women. , 1998, British journal of clinical pharmacology.